Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclax.

Cell death & disease·2026

Same author

Chronic Inflammatory Diseases and Survival among Patients with Pancreatic Cancer in the U.S. Military Health System.

The American journal of medicine·2026

Same author

SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer.

Research square·2026

Same author

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.

bioRxiv : the preprint server for biology·2026

Same author

AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology.

Cell·2026

Same author

Evaluation of medetomidine-tiletamine-zolazepam as a partially reversible field anesthesia combination for mesocarnivores.

PloS one·2026

Same journal

Accuracy of Cytology Diagnosis for Well Differentiated Neuroendocrine Tumors: Assessment by the College of American Pathologists Non-Gynecologic Slide Program.

Archives of pathology & laboratory medicine·2026

Same journal

Serum Immunofixation Electrophoresis Guidance Conflict: A Call to Harmonize.

Archives of pathology & laboratory medicine·2026

Same journal

In Reply.

Archives of pathology & laboratory medicine·2026

Same journal

Journal Club and Artificial Intelligence.

Archives of pathology & laboratory medicine·2026

Same journal

In Reply.

Archives of pathology & laboratory medicine·2026

Same journal

Using R Statistical Programming to Evaluate the Impact of the Lower Anogenital Squamous Terminology Recommendations on Cervical Biopsy Reporting at a Tertiary Care Academic Center.

Archives of pathology & laboratory medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Quality Assurance Model for Breast Cancer Prognostication Using the Modified Magee Equations.

Ian Lagerstrom¹, Daniel Neelon¹, Nena Wendzel²

¹From the Department of Pathology, Walter Reed National Military Medical Center, Bethesda, Maryland (Lagerstrom, Neelon, Wells).

Archives of Pathology & Laboratory Medicine

|July 2, 2024

Summary

This summary is machine-generated.

The Magee score (MS) acts as a quality check for the Oncotype DX recurrence score (RS) in breast cancer. This method identified significant discrepancies in 16.1% of cases, improving treatment decisions.

More Related Videos

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Jun 22, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Area of Science:

Oncology
Pathology
Genomics

Background:

The Oncotype DX recurrence score (RS) is crucial for early-stage, hormone receptor-positive breast cancer, guiding prognosis and chemotherapy benefit.
Quality assurance for RS lacks the scrutiny applied to other tests like HER2 immunohistochemistry.

Purpose of the Study:

To implement the Magee score (MS) using modified Magee equations as a quality control measure for the Oncotype DX recurrence score (RS).

Main Methods:

Calculated MS using histopathologic and immunohistochemical criteria.
Identified significant discordances where RS and MS differed by ≥10 points or risk categories.
Presented discordant cases at multidisciplinary tumor boards for clinical significance assessment.

Main Results:

Significant discrepancies between RS and MS were found in 25 of 155 cases (16.1%).
Of the discordant cases, 3 (12%) indicated issues with either the RS or histopathologic interpretation.
Concordant cases showed no identified problems with RS or interpretation.

Conclusions:

Utilizing MS as a quality check for RS enhances the accuracy of treatment decisions for breast cancer patients.
Pathologists are vital in ensuring the quality of molecular prognostic scores through histopathologic models, improving risk stratification and clinical outcomes.